Phase 1 N=30 Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions
Bioequivalence
Primary: AUC0-tlast of Favipiravir — 9641.989; 9907.170 ng*hr/mL — p=0.0000
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=27 Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer
Stage IIIA Hepatocellular Carcinoma · Stage IIIB Hepatocellular Carcinoma · Stage IIIC Hepatocellular Carcinoma
Primary: Maximum Tolerated Dose (MTD) — 240 mg of nivolumab, IV
Phase 1 N=30 Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions
Bioequivalence
Primary: AUC0-tlast — 10400.038; 9907.948 ng*hr/mL — p=0.0000
Phase 1 N=34 Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
Hyperlipidemia · HIV
Primary: AUC — 85.3; 62.8 ng*hr/mL
Phase 1 N=48 BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Lymphoma, Non-Hodgkin
Primary: Determination of the Maximum Tolerated Dose (MTD) Based on the Occurrence of Dose-limiting Toxicity (DLT) in First Cycle in Caucasian Patients — 100 Milligram (mg)
Phase 1 N=6 Augmenting Flortaucipir Dosimetry Estimates
Alzheimer's Disease
Primary: Urine Analysis - Total Integrated Radioactivity Excreted in Urine — 0.1413 megabecquerel-hours per megabecquerel
Phase 1 N=50 Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
Melanoma · Metastatic Melanoma · Solid Tumor
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths — 4; 3; 3; 3 Participants
Phase 1 N=537 Alcohol Health Education Among College Drinkers
College Student Drinking
Primary: Alcohol Consumption — 16.929; 17.988; 18.039 drinks
Phase 1 N=20 Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration
Healthy
Primary: Total Volume of Distribution (VT) of [18F]PGM299 in the Cerebellar Grey Matter (GM) for Each PET Scan — 1.211; 1.247; 1.349; 1.683 milliliter per cubic centimeter(mL/cm^3)
Phase 1 N=29 Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
Hypertension, Pulmonary
Primary: Maximum Observed Plasma Concentration (Cmax) After Administration of AMB Under Fasted Condition — 359.030; 316.505; 353.252 Nanogram per milliliter
Phase 1 N=49 Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine
Mosquito-Borne Disease
Primary: AEs Grade 3 or Higher — 0.44; 0.65; 0.63 adverse events
Phase 1 N=30 Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Liver Cancer
Primary: Pharmacokinetics Profile-- Peak of Plasma Concentration (Dose-normalized) — 2.67; 3.68; 7.11; 0.08 ng/mL/mg — p=.036
Phase 1 N=10 A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne
Acne Vulgaris
Primary: Number of Participants With Successful Engraftment of Probiotic Following a Single Application. — 2; 1 Participants
Phase 1 N=41 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.
Healthy Participants
Primary: Percentage of Participants With Adverse Events and AEs of Special Interest — 66.7; 62.5; 62.5; 75.0 Percentage of Participants
Phase 1 N=36 A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne
Acne Vulgaris
Primary: Number of Participants With Changes in Local Skin Reactions — 19; 11; 2; 1 Participants